


North Carolina Medicaid Special Bulletin

April 2019



**Attention
Physicians, Physician Assistants
and Nurse Practitioners**

**Recommended Updates to the North Carolina
Medicaid and NC Health Choice
Preferred Drug List (PDL)**

Providers are responsible for informing their billing agency of information in this bulletin.
CPT codes, descriptors and other data only are copyright 2016. American Medical Association.
All rights reserved. Applicable FARS/DFARS apply.

Attention: All Hospital Providers**Recommended Updates to the North Carolina Medicaid and NC Health Choice Preferred Drug List (PDL)**

Recommended updates to the [NC Medicaid and Health Choice Preferred Drug List \(PDL\)](#) as approved by the NC Pharmacy and Therapeutics (P&T) Committee and the NC Physician Advisory Group (PAG) were posted for the required 45-day public comment period on Apr. 2, 2019. Public comments should be submitted to dma.webmedpolicy@dhhs.nc.gov prior to the end date of **Friday, May 17, 2019**. The recommended updates to the PDL and the public comments received during the 45-day public comment period will be presented at the next PDL Review Panel meeting which is scheduled for **Wednesday, May 22, 2019, from 10 a.m. – 5 p.m.** at The State Library Building, 109 E. Jones St., Raleigh, NC 27601.

The North Carolina Medicaid and NC Health Choice PDL Review Panel was established by the NC Department of Health and Human Services (DHHS) to conduct open meetings to review and discuss recommended policies and procedures and updates related to the PDL and to address the public comments that were received during the 45-day public comment period. The administration and review of the Medicaid and NC Health Choice PDL follows the [Preferred Drug List Review Panel Guidelines and Procedures](#).

To register to speak at the meeting, send an email to Medicaid.PDLReviewMeeting@lists.ncmail.net by noon on Tuesday, May 21, 2019. Please include the name of the speaker, the represented organization and the drug name/class on which you will be speaking. You may attach any clinical information regarding the drug or the PDL drug class you wish the PDL Review Panel to review beforehand. Presentations are allowed only in the PDL drug classes with recommended updates and should not exceed three minutes.